tiprankstipranks
CRISPR Therapeutics Advances with Solid Financials and Approvals
PremiumCompany AnnouncementsCRISPR Therapeutics Advances with Solid Financials and Approvals
12d ago
Crispr Therapeutics reports Q3 EPS ($1.01), consensus ($1.42)
Premium
The Fly
Crispr Therapeutics reports Q3 EPS ($1.01), consensus ($1.42)
13d ago
Crispr Therapeutics options imply 8.9% move in share price post-earnings
Premium
The Fly
Crispr Therapeutics options imply 8.9% move in share price post-earnings
14d ago
AstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital
PremiumThe FlyAstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital
1M ago
CRISPR Therapeutics Deserves its Lofty Valuation Even with Conservative Forecasts
Premium
Market News
CRISPR Therapeutics Deserves its Lofty Valuation Even with Conservative Forecasts
2M ago
Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher
Premium
The Fly
Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher
2M ago
Crispr Therapeutics call volume above normal and directionally bullish
PremiumThe FlyCrispr Therapeutics call volume above normal and directionally bullish
3M ago
Crispr Therapeutics price target lowered to $100 from $120 at Truist
Premium
The Fly
Crispr Therapeutics price target lowered to $100 from $120 at Truist
3M ago
Mid-Cap Stocks: CRSP Offers Tremendous Growth Potential With Inherent Risks
Premium
Market News
Mid-Cap Stocks: CRSP Offers Tremendous Growth Potential With Inherent Risks
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100